Review Article Open Access
Volume 3 | Issue 2 | DOI: https://doi.org/10.33696/immunology.3.086

Pregnancy Specific Glycoproteins: A Possible Mediator of Immune Tolerance of Cancers

  • 1Program for Mathematical Genomics, Columbia University, New York, NY, USA
  • 2Departments of Systems Biology and Biomedical Informatics, Columbia University, New York, NY, USA
  • 3Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ, USA
+ Affiliations - Affiliations

Corresponding Author

Raul Rabadan, rr2579@cumc.columbia.edu;
Arnold J. Levine, alevine@ias.edu

Received Date: January 28, 2021

Accepted Date: March 19, 2021


Cancer immunotherapy relies upon the immune system recognizing and killing cancer cells. Tumors can elude recognition by readapting existing mechanisms of immune control and suppression. Here we explore the hypothesis that cancers repurpose the immune suppression employed during pregnancy to protect the allogeneic fetus. Those mechanisms are reviewed and shown to be employed both in pregnancy and by tumors. Pregnancy specific glycoproteins (PSGs) produced by fetal trophoblasts are also synthesized by a large number of tumors, which are associated with a poor overall survival of the patient. The family of PSGs may well be a useful target for future checkpoint therapy.



Pregnancy-specific glycoproteins; T-cell tolerization; Checkpoint therapy

Author Information X